

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Running title: Convalescent plasma for COVID-19

The RECOVERY Collaborative Group*

*The writing committee and trial steering committee are listed at the end of this manuscript and a complete list of collaborators in the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is provided in the Appendix.

Correspondence to: Professor Peter W Horby and Professor Martin J Landray, RECOVERY Central Coordinating Office, Richard Doll Building, Old Road Campus, Roosevelt Drive, Oxford OX3 7LF, United Kingdom.

Email: recoverytrial@ndph.ox.ac.uk

22 ABSTRACT

23 **Background:** Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-
24 2 antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate
25 the safety and efficacy of convalescent plasma in patients admitted to hospital with
26 COVID-19.

27 **Methods:** In this randomised, controlled, open-label, platform trial (Randomised
28 Evaluation of COVID-19 Therapy [RECOVERY]) several possible treatments are being
29 compared with usual care in patients hospitalised with COVID-19 in the UK. Eligible and
30 consenting patients were randomly allocated to receive either usual care plus high titre
31 convalescent plasma or usual care alone. The primary outcome was 28-day mortality.

32 **Findings:** Between 28 May 2020 and 15 January 2021, 5795 patients were randomly
33 allocated to receive convalescent plasma and 5763 to usual care alone. There was no
34 significant difference in 28-day mortality between the two groups: 1398 (24%) of 5795
35 patients allocated convalescent plasma and 1408 (24%) of 5763 patients allocated
36 usual care died within 28 days (rate ratio [RR] 1.00; 95% confidence interval [CI] 0.93 to
37 1.07; $p=0.93$). The 28-day mortality rate ratio was similar in all prespecified subgroups
38 of patients, including in those patients without detectable SARS-CoV-2 antibodies at
39 randomisation. Allocation to convalescent plasma had no significant effect on the
40 proportion of patients discharged from hospital within 28 days (66% vs. 67%; rate ratio
41 0.98; 95% CI 0.94-1.03, $p=0.50$). Among those not on invasive mechanical ventilation
42 at baseline, there was no significant difference in the proportion meeting the composite

43 endpoint of progression to invasive mechanical ventilation or death (28% vs. 29%; rate
44 ratio 0.99; 95% CI 0.93-1.05, p=0.79).

45 **Interpretation:** Among patients hospitalised with COVID-19, high-titre convalescent
46 plasma did not improve survival or other prespecified clinical outcomes.

47 **Funding:** UK Research and Innovation (Medical Research Council) and National
48 Institute of Health Research (Grant refs: MC_PC_19056; COV19-RECPLA).

49 **Keywords:** COVID-19, convalescent plasma, randomised controlled trial, platform trial

50

51

52 INTRODUCTION

53 A substantial proportion of individuals infected with severe acute respiratory syndrome
54 coronavirus 2 (SARS-CoV-2) require hospital care, which can progress to critical illness
55 with hypoxic respiratory failure. In those with severe Coronavirus Disease-19 (COVID-
56 19), immunomodulation with corticosteroids and interleukin-6 receptor antagonists has
57 been shown to improve survival.^{1,2} Treatments that effectively inhibit viral replication
58 may reduce tissue damage and allow time for the host to develop an adaptive immune
59 response that will clear the infection. To date, however, no treatment directed against
60 the virus has been shown to reduce mortality (although remdesivir may shorten the
61 duration of hospital stay).³

62 Humoral immunity is a key component of the immune response to SARS-CoV-2 and
63 matures over several weeks following infection. Anti-SARS-CoV-2 antibodies are
64 detectable at a mean of 13 days after symptom onset, but neutralising titres do not peak
65 until day 23 and there is wide variation in both the timing of seroconversion and peak
66 antibody levels between infected individuals.⁴ While patients with severe COVID-19
67 generally have higher final antibody concentrations than those with mild disease, their
68 antibody responses are delayed.⁵ Antibodies may modulate acute viral disease either
69 by a direct antiviral effect, binding and neutralizing free virus, or indirectly by activating
70 antiviral pathways such as the complement cascade, phagocytosis and cellular
71 cytotoxicity. Conversely, there is also a possibility that antibodies may enhance disease,

72 either by promoting viral entry or by pro-inflammatory mechanisms such as Fcγ receptor
73 stimulation.⁶

74 Convalescent plasma has been used for over a hundred years as passive
75 immunotherapy for influenza pneumonia, and more recently for SARS-CoV-1. While
76 observational studies have suggested it may reduce mortality in severe viral respiratory
77 infections, randomised evidence remains limited and inconclusive.⁷ Convalescent
78 plasma has been used widely outside of clinical trials, including by tens of thousands of
79 patients in the United States Food and Drugs Administration (FDA) Expanded Access
80 Program. An observational (non-randomised) analysis of 3082 patients who received
81 convalescent plasma as part of that programme, reported that 30-day mortality was
82 lower in those who had not received mechanical ventilation before transfusion with
83 higher-titre plasma (containing higher concentrations of anti-SARS-CoV-2 spike IgG)
84 compared to those transfused with lower-titre plasma.⁸ A number of randomised trials of
85 convalescent plasma in patients hospitalised with COVID-19 have been reported but
86 these trials have all been small and inconclusive.⁹⁻¹⁷ Moreover, hospitalised patients
87 with COVID-19 are heterogeneous, and any benefit of convalescent plasma could
88 depend on the stage of disease, i.e. possibly being limited to those with milder disease,
89 early in the course of their illness or those who have not mounted an effective antibody
90 response.¹² The efficacy of convalescent plasma as a treatment for patients hospitalised
91 with COVID-19 is, therefore, currently uncertain. Here, we report the results of a large
92 randomised trial to evaluate the efficacy and safety of convalescent plasma in patients
93 hospitalised with COVID-19.

94

95 **METHODS**

96 **Study design and participants**

97 The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is an investigator-
98 initiated, individually randomised, controlled, open-label, adaptive platform trial to
99 evaluate the effects of potential treatments in patients hospitalised with COVID-19.
100 Details of the trial design and results for other evaluated treatments (dexamethasone,
101 hydroxychloroquine, lopinavir-ritonavir, azithromycin and tocilizumab) have been
102 published previously.^{1,2} The trial is conducted at 177 National Health Service (NHS)
103 hospital organizations in the United Kingdom (appendix pp 5-28), supported by the
104 National Institute for Health Research Clinical Research Network. The trial is
105 coordinated by the the trial sponsor, the Nuffield Department of Population Health at the
106 University of Oxford (Oxford, UK). The trial is conducted in accordance with the
107 principles of the International Conference on Harmonisation–Good Clinical Practice
108 guidelines and approved by the UK Medicines and Healthcare products Regulatory
109 Agency (MHRA) and the Cambridge East Research Ethics Committee (ref:
110 20/EE/0101). The protocol, statistical analysis plan, and additional information are
111 available on the trial website www.recoverytrial.net.

112 Hospitalised patients of any age were eligible for the trial if they had clinically suspected
113 or laboratory-confirmed SARS-CoV-2 infection and no medical history that might, in the
114 opinion of the attending clinician, put them at significant risk if they were to participate in

115 the trial. Written informed consent was obtained from all patients or from their legal
116 representative if they were too unwell or unable to provide consent.

117 **Randomisation and masking**

118 Baseline data collected using a web-based case report form that included
119 demographics, level of respiratory support, major comorbidities, suitability of the trial
120 treatment for a particular patient and treatment availability at the trial site site (appendix
121 pp 35-37). Patients had a serum sample taken prior to randomisation for the purpose of
122 assessing the presence of antibodies against SARS-CoV-2. Eligible and consenting
123 patients were allocated in a ratio of 1:1:1 to either usual care, usual care plus
124 convalescent plasma or (from 18 September 2020) usual care plus REGN-COV2 (a
125 combination of two monoclonal antibodies directed against SARS-CoV-2 spike protein).
126 The REGN-COV2 evaluation is ongoing and not reported here. Randomisation was
127 web-based simple (unstratified) randomisation with allocation concealment (appendix
128 pp 33-34). For some patients, convalescent plasma was either declined, unavailable at
129 the trial site at the time of enrolment, or considered in the opinion of the attending doctor
130 to be definitely contraindicated (e.g. known moderate or severe allergy to blood
131 components or unwilling to receive a blood product). These patients were ineligible for
132 randomisation to the comparison of convalescent plasma versus usual care.

133 As a platform trial and in a factorial design, patients could be simultaneously
134 randomised to other treatment groups: i) hydroxychloroquine or dexamethasone or
135 azithromycin or lopinavir-ritonavir versus usual care, ii) aspirin versus usual care, and iii)
136 colchicine versus usual care (appendix pp 33-34). The trial also allowed a subsequent

137 randomisation for patients with progressive COVID-19 (evidence of hypoxia and a
138 hyper-inflammatory state) to tocilizumab versus usual care. Participants and local study
139 staff were not masked to the allocated treatment. Several of these treatment arms were
140 added to or removed from the protocol over the period that convalescent plasma was
141 evaluated (appendix pp 29-34). The trial steering committee, investigators, and all other
142 individuals involved in the trial were masked to outcome data during the trial.

143 **Procedures**

144 Convalescent plasma donors were recruited and screened by the four UK blood
145 services: NHS Blood and Transplant; Northern Ireland Blood Transfusion Service;
146 Scottish National Blood Transfusion Service; and the Welsh Blood Service (appendix pp
147 2-4 and p 29). Only plasma donations with sample to cut-off (S/CO) ratio of 6.0 or above
148 on the EUROIMMUN IgG enzyme-linked immunosorbent assay (ELISA) test targeting
149 the spike (S) glycoprotein (PerkinElmer, London, UK) were supplied for the RECOVERY
150 trial use (appendix p 29). This assay cut-off was previously demonstrated to be
151 associated with the presence of neutralising antibody titres of $\geq 1:100$ in convalescent
152 plasma.¹⁸ The United States Food and Drug Administration (US FDA) have determined
153 that convalescent plasma with a EUROIMMUN S/CO of ≥ 3.5 qualifies as high-titre and
154 can be used for the treatment of hospitalised patients under an Emergency use
155 Authorization (EUA).¹⁹ For those allocated convalescent plasma, two units (275mls \pm
156 75mls) were given intravenously, the first as soon as possible after randomisation and
157 the second (from a different donor) the following day and at least 12 hours after the first.

158 Early safety outcomes were recorded using an online form 72 hours following
159 randomisation (appendix pp 38-42). An online follow-up form was completed when
160 patients were discharged, had died, or at 28 days after randomisation, whichever
161 occurred earlier (appendix pp 43-49). Information was recorded on adherence to
162 allocated trial treatment, receipt of other COVID-19 treatments, duration of admission,
163 receipt of respiratory or renal support, and vital status (including cause of death). In
164 addition, routine health care and registry data were obtained including information on
165 vital status at day 28 (with date and cause of death); discharge from hospital; and
166 receipt of respiratory support or renal replacement therapy.

167 **Measurement of participant baseline SARS-CoV-2 serostatus**

168 Baseline SARS-CoV-2 serostatus for each participant was determined using serum
169 samples taken at the time of randomisation. Analysis was performed at a central
170 laboratory using a validated 384-well plate indirect ELISA (appendix p 29).²⁰
171 Participants were categorised as seropositive or seronegative using a predefined assay
172 threshold that has $\geq 99\%$ sensitivity and specificity in detecting individuals with SARS-
173 CoV-2 infection at least 20 days previously.²⁰

174 **Outcomes**

175 Outcomes were assessed at 28 days after randomisation, with further analyses
176 specified at six months. The primary outcome was all-cause mortality. Secondary
177 outcomes were time to discharge from hospital and, among patients not receiving
178 invasive mechanical ventilation at randomisation, subsequent receipt of invasive
179 mechanical ventilation (including extra-corporeal membrane oxygenation) or death.

180 Prespecified, subsidiary clinical outcomes included receipt of ventilation, time to
181 successful cessation of invasive mechanical ventilation (defined as removal of invasive
182 mechanical ventilation within, and survival to, 28 days), and use of renal dialysis or
183 haemofiltration.

184 Prespecified safety outcomes were transfusion related adverse events at 72 hours
185 following randomisation (worsening respiratory status, suspected transfusion reaction,
186 fever, hypotension, haemolysis, and thrombotic events), cause-specific mortality, and
187 major cardiac arrhythmia. Information on serious adverse reactions to convalescent
188 plasma was collected in an expedited fashion via the existing NHS Serious Hazards Of
189 Transfusion (SHOT) haemovigilance scheme.

190 **Statistical Analysis**

191 In accordance with the statistical analysis plan, an intention-to-treat comparison was
192 conducted between patients randomised to convalescent plasma and patients
193 randomised to usual care in those for whom convalescent plasma was both available
194 and suitable as a treatment. For the primary outcome of 28-day mortality, the log-rank
195 observed minus expected statistic and its variance were used both to test the null
196 hypothesis of equal survival curves (i.e. the log-rank test) and to calculate the one-step
197 estimate of the average mortality rate ratio. We constructed Kaplan-Meier survival
198 curves to display cumulative mortality over the 28-day period. We used similar methods
199 to analyse time to hospital discharge and successful cessation of invasive mechanical
200 ventilation, with those patients who died in hospital right-censored on day 29. Median
201 time to discharge was derived from Kaplan-Meier estimates. For the prespecified,
202 composite, secondary outcome of progression to invasive mechanical ventilation or

203 death within 28 days (among those not receiving invasive mechanical ventilation at
204 randomisation) and the subsidiary clinical outcomes of receipt of ventilation and use of
205 haemodialysis or haemofiltration, the precise dates were not available and so the risk
206 ratio was estimated instead. (Through the play of chance, a slightly lower proportion of
207 males were allocated convalescent plasma than usual care; analyses adjusted for sex
208 are provided in the appendix [webtable 7] and are virtually identical to the main results
209 shown.) Sensitivity analyses of the primary and secondary outcomes were conducted
210 among those patients with a positive PCR test for SARS-CoV-2.

211 Prespecified analyses of the primary outcome were performed in seven subgroups
212 defined by characteristics at randomisation: age, sex, ethnicity, level of respiratory
213 support received, days since symptom onset, use of systemic corticosteroids, and
214 presence of anti-SARS-CoV-2 antibody. Observed effects within these subgroup
215 categories were compared using a chi-squared test for heterogeneity or trend. *Post-hoc*
216 exploratory analyses included further examination by days since symptom according to
217 four rather than two levels and by level of respiratory support by sub-dividing the
218 'oxygen only' group into three sub-categories. In late 2020, a new SARS-CoV-2 variant,
219 named B.1.1.7, with multiple substitutions in the receptor binding domain of the spike
220 glycoprotein emerged in southeast England and rapidly grew to become the dominant
221 virus variant throughout the UK.²¹ Convalescent plasma from individuals infected prior
222 to the emergence of B.1.1.7 show a modest reduction in ability to neutralize B.1.1.7
223 compared with earlier SARS-CoV-2 virus variants.²² The clinical significance of this
224 reduced in vitro neutralisation is not known. To assess if there was evidence of a
225 difference in the effectiveness of convalescent plasma before and after the emergence

226 of B.1.1.7, a further *post-hoc* exploratory analysis was done of the primary outcome
227 comparing effects in those randomised before 1 December 2020 with those randomised
228 from 1 December 2020 onwards.²¹

229 Estimates of rate and risk ratios are shown with 95% confidence intervals. All p-values
230 are 2-sided and are shown without adjustment for multiple testing. The full database is
231 held by the trial team who pooled the data from trial sites and performed the analyses at
232 the Nuffield Department of Population Health, University of Oxford.

233 Analyses were performed using SAS version 9.4 and R version 3.4. The trial is
234 registered with ISRCTN (50189673) and clinicaltrials.gov (NCT04381936).

235 **Sample size and decision to stop enrolment**

236 As stated in the protocol, appropriate sample sizes could not be estimated when the trial
237 was being planned at the start of the COVID-19 pandemic. During the trial, external
238 data suggested that any benefits of antibody-based therapies may be greater among
239 those patients who had not raised an adequate antibody response of their own.¹²
240 Consequently, while still blind to the results of the trial, the RECOVERY steering
241 committee determined that the trial should enrol sufficient patients to provide at least
242 90% power at a two-sided p-value of 0.01 to detect a proportional reduction in 28-day
243 mortality of one-fifth among those patients with and, separately, without detectable
244 SARS-CoV-2 antibodies at randomisation (appendix p 34).

245 On 7th January 2021, the independent data monitoring committee (DMC) conducted a
246 routine review of the data and recommended that the chief investigators pause the

247 recruitment to the convalescent plasma comparison in those patients receiving invasive
248 mechanical ventilation (including extracorporeal membrane oxygenation) at the time of
249 randomisation. At the same time, the DMC recommended that recruitment to the
250 convalescent plasma comparison continue for all other eligible patients.

251 On 14th January 2021, the DMC conducted another routine review of the data and
252 notified the chief investigators that there was no convincing evidence that further
253 recruitment would provide conclusive proof of worthwhile mortality benefit either overall
254 or in any pre-specified subgroup. The DMC therefore recommended that recruitment to
255 the convalescent plasma portion of the study should cease and follow-up be completed.
256 Enrolment of patients to the convalescent plasma group was closed on 15th January
257 2021 and the preliminary result for the primary outcome was made public.

258 **Role of the funding source**

259 The funders of the trial had no role in trial design, data collection, data analysis, data
260 interpretation, or writing of the report. The corresponding authors had full access to all
261 the data in the study and had final responsibility for the decision to submit for
262 publication.

263

264

265 **RESULTS**

266 **Patients**

267 Between 28 May 2020 and 15 January 2021, 13127 (81%) of 16287 patients enrolled
268 into the RECOVERY trial, were eligible to be randomised to convalescent plasma (that
269 is, convalescent plasma was available in the hospital at the time and the patient had no
270 known contraindication to convalescent plasma (figure 1). Of these, 5795 were
271 randomised to convalescent plasma plus usual care and 5763 were randomised to
272 usual care alone (figure 1), with the remainder being randomised to receive REGN-
273 COV2. The mean age of trial patients in this comparison was 63.5 (SD 14.7) years and
274 the median time from symptom onset to randomization was 9 days (IQR 6 – 12) (table
275 1, webtable 1). At randomisation, 617 (5%) were receiving invasive mechanical
276 ventilation, 10044 (87%) were receiving oxygen only (with or without non-invasive
277 respiratory support), and 897 (8%) were receiving no oxygen therapy (webtable 1). 92%
278 of patients were receiving corticosteroids at time of randomisation.

279 Of the 9385 (81%) patients for whom a baseline serology result was available, 5774
280 (62%) were SARS-CoV-2 antibody seropositive (webtable 1). Patients were more likely
281 to be seronegative if they were older, female, white, had shorter duration of symptoms,
282 were receiving less intensive respiratory support, or were SARS-CoV-2 RNA negative
283 by PCR (webtable 2). There was an imbalance in the availability of a baseline serology
284 sample, with more missing samples in the usual care arm (table1). (This likely reflects a
285 mistaken belief by some trial staff that a serology sample was only required in patients
286 allocated to convalescent plasma.)

287 Among the 5795 patients allocated to convalescent plasma, 4675 (81%) received two
288 units, 671 (12%) received one unit, and 449 (8%) received no units (webtable 3). Only
289 two patients received both convalescent plasma units from the same donor. Forty-five
290 (1%) patients allocated to usual care received convalescent plasma. Use of
291 corticosteroids and remdesivir following randomisation was similar among patients
292 allocated convalescent plasma and among those allocated usual care (webtable 3).
293 Fewer patients received tocilizumab or sarilumab in the convalescent plasma group (8%
294 vs. 10%, webtable 3).

295 There was no significant difference in 28-day mortality between the two randomised
296 groups, with death reported in 1398 of 5795 patients (24%) allocated convalescent
297 plasma versus 1408 of 5763 patients (24%) allocated usual care (rate ratio, 1.00; 95%
298 confidence interval [CI], 0.93 to 1.07; $P=0.93$) (figure 2). We observed similar results
299 across all subgroups with no evidence of heterogeneity of effect in either the pre-
300 specified (figure 3) or the exploratory *post-hoc* (webfigure 1) subgroup analyses, and
301 similar results in analyses restricted to those patients with a positive SARS-CoV-2 test
302 (rate ratio 1.00; 95% CI, 0.93 to 1.08; $P=0.98$). Although 28-day mortality was higher
303 among those patients who were seronegative at randomisation, the proportional effect
304 of allocation to convalescent plasma on 28-day mortality was similar among
305 seropositive patients (19% versus 18%; rate ratio, 1.05; 95% CI, 0.93 to 1.19) and
306 seronegative patients (32% versus 34%; rate ratio, 0.94; 95% CI, 0.84 to 1.06) (figure
307 3; webfigure 2).

308 The median time to discharge was 11 days in both those allocated convalescent plasma
309 and those allocated usual care, and allocation to convalescent plasma was associated
310 with a similar probability of discharge alive within 28 days compared to usual care (66%
311 vs. 67%, rate ratio 0.98 95% CI 0.94 to 1.03, $p=0.50$) (table 2). Among those not
312 receiving invasive mechanical ventilation at baseline, the number of patients
313 progressing to the prespecified composite secondary outcome of invasive mechanical
314 ventilation or death was similar for those allocated to convalescent plasma or usual care
315 (28% versus 29%, risk ratio 0.99 95% CI 0.93 to 1.05, $p=0.79$) (table 2). For both of
316 these secondary outcomes, there was some evidence of heterogeneity by patient
317 SARS-CoV-2 antibody test result, with slightly more favourable outcomes with
318 convalescent plasma seen among seronegative than among seropositive patients
319 (webfigures 3 and 4). Results were consistent across all other pre-specified subgroups
320 of patients.

321 We observed no significant differences in the prespecified subsidiary clinical outcomes
322 of use of ventilation, successful cessation of invasive mechanical ventilation, or
323 progression to use of renal replacement therapy (table 2).

324 We observed no significant differences in cause-specific mortality (webtable 4). Within
325 the first 72 hours after randomisation, severe allergic reactions were reported for 16
326 patients in the convalescent plasma group vs. 2 patients in the usual care group. The
327 frequency of sudden worsening in respiratory status, temperature $>39^{\circ}\text{C}$ or $\geq 2^{\circ}\text{C}$ rise
328 above baseline, sudden hypotension, clinical haemolysis, and thrombotic events were
329 broadly similar in the two groups (webtable 5). We also observed no significant
330 differences in the frequency of major cardiac arrhythmia (webtable 6). There were 13

331 serious adverse reactions reported to SHOT: 9 patients with pulmonary reactions
332 (including 3 deaths possibly related to transfusion), and 4 patients with serious febrile,
333 allergic or hypotensive reactions (all of whom recovered).

334 **DISCUSSION**

335 The results of this large, randomised trial show that convalescent plasma did not
336 improve survival or other clinical outcomes in patients hospitalised with COVID-19. The
337 results were consistent across subgroups of age, sex, ethnicity, duration of symptoms
338 prior to randomisation, level of respiratory support received at randomisation, and use of
339 corticosteroids. Nine other randomised trials of convalescent plasma for the treatment of
340 hospitalised patients with COVID-19 have been reported, which, together, have
341 included fewer than 200 deaths.⁹⁻¹⁷ None of these trials have demonstrated a beneficial
342 effect of convalescent plasma on mortality. Taking the results of all trials together,
343 including RECOVERY (which is more than ten times larger than all other trials
344 combined) allocation to convalescent plasma does not improve mortality (mortality RR
345 0.99, 95% CI 0.92–1.06, $p=0.77$ (figure 4).

346 It has been suggested that the benefits of convalescent plasma may depend on the
347 transfused neutralising titre, and that using plasma with lower titres could explain
348 negative results from previous randomised trials. In RECOVERY, all convalescent
349 plasma was supplied via the UK National Blood Services using standardised laboratory
350 processing. Convalescent donors were chosen based on high anti-spike IgG levels,
351 using an ELISA that has been shown to correlate well with neutralising antibody.²³⁻²⁵ We
352 used a EUROIMMUN S/CO ratio of ≥ 6 for plasma to qualify for use in this trial, which is
353 substantially above the level of ≥ 3.5 that the US FDA recognises as high titre.¹⁹

354 Recipients received plasma from two different donors to increase the chance that at
355 least one contained higher levels of neutralising antibodies.

356 The presence of anti-SARS-CoV-2 antibodies in recipients prior to transfusion with
357 convalescent plasma has also been cited as a possible reason for a lack of effect of
358 convalescent plasma.¹² In this trial we found that around 38% of patients were
359 seronegative at randomisation and, although they had a markedly higher 28-day
360 mortality risk than seropositive patients, we did not observe a survival benefit from
361 convalescent plasma in these seronegative patients. There was, however, a suggestion
362 of small improvements (proportional risk reduction of about one tenth) in the probability
363 of successful discharge from hospital by day 28 and of progressing to invasive
364 mechanical ventilation or death in seronegative patients allocated to convalescent
365 plasma. The apparent heterogeneity in these secondary outcomes according to
366 serostatus should be interpreted with a great deal of caution however, not least because
367 (perhaps by chance or perhaps as a result of conscious or unconscious decisions about
368 who to collect a serological sample from) the seronegative convalescent plasma
369 recipients were slightly younger than the seronegative usual care group, whereas
370 seropositive convalescent plasma recipients were slightly older than the seropositive
371 usual care group (webtable 2). Due to the known strong effects of age on mortality risk,
372 even these minor age imbalances could have led to a spuriously lower relative relative
373 risk of death in the seronegative convalescent plasma recipients and a spuriously higher
374 relative risk of death in the seropositive convalescent plasma recipients.

375 It has also been suggested that antibody based therapies are likely to be most effective
376 in the early stages of COVID-19, when viral replication dominates.²⁶ We did not identify

377 a benefit when we stratified by time since onset of illness in the main analysis (or in an
378 exploratory analysis further subdividing time since illness onset). However, RECOVERY
379 only included patients admitted to hospital and does not, therefore, address whether
380 convalescent plasma may be of benefit if given early after SARS-CoV-2 infection and
381 before the onset of significant disease.

382 Following randomisation to convalescent plasma, patients with hypoxia and a raised C-
383 reactive protein (CRP ≥ 75 mg/L) were eligible for a second randomisation to usual care
384 versus usual care plus tocilizumab. Although a slightly lower proportion of patients
385 allocated convalescent plasma subsequently received tocilizumab than patients
386 allocated usual care (8% vs 10%, webtable 3), and although tocilizumab itself reduces
387 28-day mortality by around 15%,¹ this difference in the likelihood of progression to the
388 second randomisation is far too small to have had any material impact on our estimate
389 of the effect of convalescent plasma on mortality (or other outcomes).

390 SARS-CoV-2 is an RNA virus with antigenic variability. The efficacy of convalescent
391 plasma is likely to depend on the 'match' between the strain-specific transfused anti-
392 SARS-CoV-2 antibodies in donor plasma and the infecting virus variant in the recipient.
393 In December 2020 a new SARS-CoV-2 variant (B.1.1.7) was detected in the South East
394 and East of England, with an earliest date of detection in September, which spread
395 rapidly to become the dominant SARS-CoV-2 variant, in most regions of the UK, by
396 January 2021.²⁷ Whilst B.1.1.7 has changes in the spike glycoprotein that could
397 theoretically modify antigenicity, only modest reductions in neutralisation by
398 convalescent plasma have been reported.²⁸ Consistent with this, we did not identify any

399 evidence of a differential effect of convalescent plasma prior to and after the emergence
400 of B.1.1.7 in the UK.²²

401 During an epidemic caused by a novel virus, convalescent plasma is an appealing
402 treatment as it may be available within weeks of the outbreak, long before other
403 targeted therapies are available. Consequently, convalescent plasma has been widely
404 used for COVID-19 outside of clinical trials but, until now, there has been insufficient
405 evidence from randomised trials to reliably assess its safety and efficacy.⁸ In
406 RECOVERY, the largest clinical trial of convalescent plasma for any infectious
407 indication, high-titre convalescent plasma did not improve survival or other prespecified
408 clinical outcomes.

409

410 **Contributors**

411 This manuscript was initially drafted by the PWH and MJL, further developed by the
412 Writing Committee, and approved by all members of the trial steering committee. PWH
413 and MJL vouch for the data and analyses, and for the fidelity of this report to the trial
414 protocol and data analysis plan. PWH, LE, LP, MM, JKB, LCC, SNF, TJ, KJ, WSL, AM,
415 KR, EJ, DR, RH, and MJL designed the trial and trial protocol. MM, AR, G P-A, NB, TG,
416 DZ, ST, NA, AU, JW, GK, TB, SS, RH, the Data Linkage team at the RECOVERY
417 Coordinating Centre, Health Records, and Local Clinical Centre staff listed in the
418 appendix collected the data. ES, NS, and JRE did the statistical analysis. LE, DR, and
419 the blood and transfusion service staff listed in the appendix coordinated the collection
420 and supply of convalescent plasma. SH ran the ELISA assays on patient samples. All
421 authors contributed to data interpretation and critical review and revision of the
422 manuscript. PWH and MJL had access to the trial data and had final responsibility for
423 the decision to submit for publication.

424 **Writing Committee (on behalf of the RECOVERY Collaborative Group):**

425 Professor Peter W Horby PhD FRCP,^{a,*} Lise Estcourt PhD FRCP FRCPATH,^{b,c,g,*} Leon
426 Peto PhD,^{a,d*} Professor Jonathan R Emberson PhD,^{e,f} Natalie Staplin PhD,^{e,f} Enti
427 Spata,^{e,f} Guilherme Pessoa-Amorim MD,^{d,g} Mark Cambell FRCPATH,^{a,d} Alistair Roddick
428 MBBS,^{d,e} Nigel J Brunskill,^h Tina George,ⁱ Daniel Zehnder,^j Simon Tiberi,^k Ni Ni Aung,^l
429 Alison Uriel,^m John Widdrington,ⁿ George Koshy,^o Thomas Brown,^p Stephen Scott
430 PhD,^q J Kenneth Baillie MD PhD,^r Professor Maya H Buch PhD FRCP,^s Professor Lucy
431 C Chappell PhD,^t Professor Jeremy N Day PhD FRCP,^{a,u} Professor Saul N Faust PhD

432 FRCPCH,^v Professor Thomas Jaki PhD,^{w,x} Katie Jeffery PhD FRCP FRCPATH,^c
433 Professor Edmund Juszczak MSc,^y Professor Wei Shen Lim DM,^{y,z} Marion Mafham
434 MD,^{c,†} Professor Alan Montgomery PhD,^y Professor Andrew D Mumford PhD,^A Kathryn
435 Rowan PhD,^B Professor Guy Thwaites PhD FRCP,^{a,u} Professor David J. Roberts PhD
436 FRCPATH^{b,c,g†} Professor Richard Haynes DM,^{d,e,†} Professor Martin J Landray PhD
437 FRCP.^{d,e,f,†}

438

439 ^a Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

440 ^b NHS Blood and Transplant Service, Oxford, United Kingdom

441 ^c Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

442 ^d Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

443 ^e Nuffield Department of Population Health, University of Oxford, Oxford, United
444 Kingdom

445 ^f MRC Population Health Research Unit, University of Oxford, Oxford, United Kingdom

446 ^g NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS
447 Foundation Trust, Oxford, United Kingdom

448 ^h Department of Cardiovascular Science, , College of Life Sciences, University of
449 Leicester, Leicester, United Kingdom

450 ⁱ Basildon and Thurrock Hospitals NHS Foundation Trust, Basildon, United Kingdom^j

451 North Cumbria Integrated Care NHS Foundation Trust, Carlisle, United Kingdom

452 ^k Barts Health NHS Foundation Trust, London, United Kingdom

453 ^l North Tees & Hartlepool NHS Foundation Trust, Stockton-on-Tees, United Kingdom

454 ^m North Manchester General Hospital, Pennine Acute Hospitals NHS Trust, Bury, United
455 Kingdom

456 ⁿ Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, United
457 Kingdom

458 ^o North West Anglia NHS Foundation Trust, Peterborough, United Kingdom

459 ^p Portsmouth Hospitals NHS Foundation Trust, Portsmouth, United Kingdom

460 ^q The Countess of Chester Hospital NHS Foundation Trust, Chester, United Kingdom

461 ^r Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom

462 ^s Centre for Musculoskeletal Research, University of Manchester, Manchester, and
463 NIHR Manchester Biomedical Research Centre, United Kingdom.

464 ^t School of Life Course Sciences, King's College London, London, United Kingdom

465 ^u Oxford University Clinical Research Unit, Ho Chi Minh City, Viet Nam

466 ^v NIHR Southampton Clinical Research Facility and Biomedical Research Centre,
467 University Hospital Southampton NHS Foundation Trust and University of Southampton,
468 Southampton, United Kingdom

469 ^w Department of Mathematics and Statistics, Lancaster University, Lancaster, United
470 Kingdom

471 ^x MRC Biostatistics Unit, University of Cambridge, Cambridge, United Kingdom

472 ^y School of Medicine, University of Nottingham, Nottingham, United Kingdom

473 ^z Respiratory Medicine Department, Nottingham University Hospitals NHS Trust,
474 Nottingham, United Kingdom

475 ^A School of Cellular and Molecular Medicine, University of Bristol, Bristol, United
476 kingdom

477 ^B Intensive Care National Audit & Research Centre, London, United Kingdom

478 ^{*,†} equal contribution

479 **Data Monitoring Committee**

480 Peter Sandercock, Janet Darbyshire, David DeMets, Robert Fowler, David Lalloo, Ian
481 Roberts (until December 2020), Mohammed Munavvar (from January 2021), Janet
482 Wittes.

483

484

485 **Declaration of interests**

486 The authors have no conflict of interest or financial relationships relevant to the
487 submitted work to disclose. No form of payment was given to anyone to produce the
488 manuscript. All authors have completed and submitted the ICMJE Form for Disclosure
489 of Potential Conflicts of Interest. The Nuffield Department of Population Health at the
490 University of Oxford has a staff policy of not accepting honoraria or consultancy fees
491 directly or indirectly from industry (see [https://www.ndph.ox.ac.uk/files/about/ndph-](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)
492 [independence-of-research-policy-jun-20.pdf](https://www.ndph.ox.ac.uk/files/about/ndph-independence-of-research-policy-jun-20.pdf)).

493 **DATA SHARING**

494 The protocol, consent form, statistical analysis plan, definition & derivation of clinical
495 characteristics & outcomes, training materials, regulatory documents, and other relevant
496 trial materials are available online at www.recoverytrial.net. As described in the protocol,
497 the trial steering committee will facilitate the use of the trial data and approval will not be
498 unreasonably withheld. Deidentified participant data will be made available to bona fide
499 researchers registered with an appropriate institution within 3 months of publication.
500 However, the steering committee will need to be satisfied that any proposed publication
501 is of high quality, honours the commitments made to the trial patients in the consent
502 documentation and ethical approvals, and is compliant with relevant legal and
503 regulatory requirements (e.g. relating to data protection and privacy). The steering
504 committee will have the right to review and comment on any draft manuscripts prior to
505 publication. Data will be made available in line with the policy and procedures described

506 at: <https://www.ndph.ox.ac.uk/data-access>. Those wishing to request access should
507 complete the form at
508 https://www.ndph.ox.ac.uk/files/about/data_access_enquiry_form_13_6_2019.docx
509 and e-mailed to: data.access@ndph.ox.ac.uk

510

511 **ACKNOWLEDGMENTS**

512 Above all, we would like to thank the thousands of patients who participated in this trial.
513 We would also like to thank the many doctors, nurses, pharmacists, other allied health
514 professionals, and research administrators at 176 NHS hospital organisations across
515 the whole of the UK, supported by staff at the National Institute of Health Research
516 (NIHR) Clinical Research Network, NHS DigiTrials, NHS Blood and Transplant, the
517 Scottish National Blood Transfusion Service, Welsh Blood Service, Northern Ireland
518 Blood Transfusion Service, Public Health England, Department of Health & Social Care,
519 the Intensive Care National Audit & Research Centre, Public Health Scotland, National
520 Records Service of Scotland, the Secure Anonymised Information Linkage (SAIL) at
521 University of Swansea, and the NHS in England, Scotland, Wales and Northern Ireland.

522 The RECOVERY trial is supported by a grant to the University of Oxford from UK
523 Research and Innovation (UKRI)/NIHR (Grant reference: MC_PC_19056), by
524 Department of Health and Social Care (DHSC)/UKRI/NIHR COVID-19 Rapid Response
525 Grant (COV19-RECPLA). and by core funding provided by NIHR Oxford Biomedical
526 Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for
527 International Development, Health Data Research UK, the Medical Research Council

528 Population Health Research Unit, the NIHR Health Protection Unit in Emerging and
529 Zoonotic Infections, NHS Blood and Transplant Research and Development Funding,
530 European Union's Horizon 2020 research and innovation programme (SUPPORT-E -
531 101015756), and NIHR Clinical Trials Unit Support Funding. TJ is supported by a grant
532 from UK Medical Research Council (MC_UU_0002/14) and an NIHR Senior Research
533 Fellowship (NIHR-SRF-2015-08-001). WSL is supported by core funding provided by
534 NIHR Nottingham Biomedical Research Centre. Abbvie contributed some supplies of
535 lopinavir-ritonavir for use in this trial. Tocilizumab was provided free of charge for this
536 trial by Roche Products Limited. REGN-COV2 was provided free of charge for this trial
537 by Regeneron. The collection of plasma was funded by the DHSC through core funding
538 and funding under COVID-19 and EU SoHo Grant.

539 The views expressed in this publication are those of the authors and not necessarily
540 those of the NHS, the NIHR, NHS Blood and Transplant, the DHSC, or the EU.

541

542

543 **References**

- 544 1. Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to
545 hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled,
546 open-label, platform trial. *medRxiv* 2021: 2021.02.11.21249258.
- 547 2. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients
548 with Covid-19 - Preliminary Report. *N Engl J Med* 2020.
- 549 3. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-
550 19 - Final Report. *N Engl J Med* 2020; **383**(19): 1813-26.
- 551 4. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of
552 neutralizing antibody responses in the three months following SARS-CoV-2 infection in
553 humans. *Nat Microbiol* 2020; **5**(12): 1598-607.
- 554 5. Li K, Huang B, Wu M, et al. Dynamic changes in anti-SARS-CoV-2 antibodies
555 during SARS-CoV-2 infection and recovery from COVID-19. *Nat Commun* 2020; **11**(1):
556 6044.
- 557 6. Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement
558 and SARS-CoV-2 vaccines and therapies. *Nat Microbiol* 2020; **5**(10): 1185-91.
- 559 7. Devasenapathy N, Ye Z, Loeb M, et al. Efficacy and safety of convalescent
560 plasma for severe COVID-19 based on evidence in other severe respiratory viral
561 infections: a systematic review and meta-analysis. *CMAJ* 2020; **192**(27): E745-E55.
- 562 8. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels
563 and the Risk of Death from Covid-19. *New England Journal of Medicine* 2021.

- 564 9. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to
565 Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A
566 Randomized Clinical Trial. *JAMA* 2020; **324**(5): 460-70.
- 567 10. Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the
568 management of moderate covid-19 in adults in India: open label phase II multicentre
569 randomised controlled trial (PLACID Trial). *BMJ* 2020; **371**: m3939.
- 570 11. Simonovich VA, Burgos Pratz LD, Scibona P, et al. A Randomized Trial of
571 Convalescent Plasma in Covid-19 Severe Pneumonia. *N Engl J Med* 2020.
- 572 12. Gharbharan A, Jordans CCE, GeurtsvanKessel C, et al. Convalescent Plasma
573 for COVID-19. A randomized clinical trial. *medRxiv* 2020: 2020.07.01.20139857.
- 574 13. Bajpai M, Kumar S, Maheshwari A, et al. Efficacy of Convalescent Plasma
575 Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot
576 Randomized Controlled Trial. *medRxiv* 2020: 2020.10.25.20219337.
- 577 14. AlQahtani M, Abdulrahman A, Almadani A, et al. Randomized controlled trial of
578 convalescent plasma therapy against standard therapy in patients with severe COVID-
579 19 disease. *medRxiv* 2020: 2020.11.02.20224303.
- 580 15. Balcells ME, Rojas L, Le Corre N, et al. Early Anti-SARS-CoV-2 Convalescent
581 Plasma in Patients Admitted for COVID-19: A Randomized Phase II Clinical Trial.
582 *medRxiv* 2020: 2020.09.17.20196212.
- 583 16. Ray Y, Paul SR, Bandopadhyay P, et al. Clinical and immunological benefits of
584 convalescent plasma therapy in severe COVID-19: insights from a single center open
585 label randomised control trial. *medRxiv* 2020: 2020.11.25.20237883.

- 586 17. Avendaño-Solà C, Ramos-Martínez A, Muñoz-Rubio E, et al. Convalescent
587 Plasma for COVID-19: A multicenter, randomized clinical trial. *medRxiv* 2020:
588 2020.08.26.20182444.
- 589 18. Harvala H, Robb M, Watkins N, et al. Convalescent plasma therapy for the
590 treatment of patients with COVID-19: Assessment of methods available for antibody
591 detection and their correlation with neutralising antibody levels. *medRxiv* 2020:
592 2020.05.20.20091694.
- 593 19. U.S. Department of Health and Human Services Food and Drug Administration.
594 Letter of Authorization, Reissuance of Convalescent Plasma EUA February 4, 2021.
595 2021.
- 596 20. National Sars-CoV-Serology Assay Evaluation Group. Performance
597 characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark
598 comparison. *Lancet Infect Dis* 2020.
- 599 21. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of
600 SARS-CoV-2 lineage B.1.1.7 in England. *Science* 2021: eabg3055.
- 601 22. Wang P, Liu L, Iketani S, et al. Increased Resistance of SARS-CoV-2 Variants
602 B.1.351 and B.1.1.7 to Antibody Neutralization. *bioRxiv* 2021.
- 603 23. Harvala H, Robb ML, Watkins N, et al. Convalescent plasma therapy for the
604 treatment of patients with COVID-19: Assessment of methods available for antibody
605 detection and their correlation with neutralising antibody levels. *medRxiv* 2020:
606 2020.05.20.20091694.

- 607 24. Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five
608 commercially available serologic assays to detect antibodies to SARS-CoV-2 and
609 identify individuals with high neutralizing titers. *J Clin Microbiol* 2020.
- 610 25. Therrien C, Serhir B, Belanger-Collard M, et al. Multicenter Evaluation of the
611 Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of ten
612 high throughput serological assays used in Clinical Laboratories. *J Clin Microbiol* 2020.
- 613 26. Libster R, Perez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to
614 Prevent Severe Covid-19 in Older Adults. *N Engl J Med* 2021.
- 615 27. Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7
616 in England: Insights from linking epidemiological and genetic data. *medRxiv* 2021:
617 2020.12.30.20249034.
- 618 28. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2
619 B.1.1.7 variant by convalescent and vaccine sera. *Cell* 2021.
- 620 29. Rasheed AM, Fatak DF, Hashim HA, et al. The therapeutic potential of
621 convalescent plasma therapy on treating critically-ill COVID-19 patients residing in
622 respiratory care units in hospitals in Baghdad, Iraq. *Infez Med* 2020; **28**(3): 357-66.
- 623 30. Hamdy Salman O, Ail Mohamed HS. Efficacy and safety of transfusing plasma
624 from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded
625 controlled preliminary study. *Egyptian Journal of Anaesthesia* 2020; **36**(1): 264-72.
- 626
- 627

628 **Table 1: Baseline characteristics**

	Convalescent Plasma (n=5795)	Usual Care (n=5763)
Age, years	63.6 (14.7)	63.4 (14.6)
<70*	3705 (64)	3748 (65)
70 to 79	1310 (23)	1280 (22)
≥80	780 (13)	735 (13)
Sex		
Men	3643 (63)	3787 (66)
Women†	2152 (37)	1976 (34)
Ethnicity		
White	4362 (75)	4293 (74)
Black, Asian, and minority ethnic	853 (15)	889 (15)
Unknown	580 (10)	581 (10)
Number of days since symptom onset	9 (6-12)	9 (6-12)
Number of days since admission to hospital	2 (1-3)	2 (1-4)
Respiratory support received		
No oxygen received	442 (8)	455 (8)
Oxygen only‡	5051 (87)	4993 (87)
Invasive mechanical ventilation	302 (5)	315 (5)
Previous diseases		
Diabetes	1535 (26)	1569 (27)
Heart disease	1267 (22)	1309 (23)
Chronic lung disease	1385 (24)	1328 (23)
Tuberculosis	20 (<1)	23 (<1)
HIV	17 (<1)	19 (<1)
Severe liver disease§	70 (1)	72 (1)
Severe kidney impairment¶	323 (6)	293 (5)
Any of the above	3203 (55)	3222 (56)
SARS-CoV-2 PCR test result		
Positive	5581 (96)	5559 (96)
Negative	125 (2)	113 (2)
Unknown	89 (2)	91 (2)
Patient SARS-CoV-2 antibody test result		
Positive	3022 (52)	2752 (48)
Negative	1982 (34)	1629 (28)
Missing	791 (14)	1382 (24)
Corticosteroids received		
Yes	5370 (93)	5311 (92)
No	391 (7)	413 (7)
Not recorded	34 (1)	39 (1)
Other randomised treatments		
Lopinavir-ritonavir	5 (<1)	14 (<1)
Dexamethasone	3 (<1)	3 (<1)
Hydroxychloroquine	1 (<1)	0
Azithromycin	587 (10)	585 (10)
Colchicine	792 (14)	791 (14)
Aspirin	1266 (22)	1207 (21)

Data are mean (SD), n (%), or median (IQR). *Includes 26 children (<18 years). † Includes 28 pregnant women. ‡ Includes non-invasive ventilation. § Defined as requiring ongoing specialist care. ¶ Defined as estimated glomerular filtration rate <30 mL/min per 1.73 m²

629

630 **Table 2: Primary, Secondary and Subsidiary Outcomes**

	Convalescent plasma (n=5795)	Usual Care (n=5763)	RR (95% CI)	p value
Primary outcome				
Mortality at 28 days	1398 (24%)	1408 (24%)	1.00 (0.93-1.07)	0.93
Secondary outcomes				
Median duration of hospitalization, days	11	11	-	-
Discharged from hospital within 28 days	3850 (66%)	3846 (67%)	0.98 (0.94-1.03)	0.50
Invasive mechanical ventilation or death*	1561/5493 (28%)	1561/5448 (29%)	0.99 (0.93-1.05)	0.79
Invasive mechanical ventilation	670/5493 (12%)	681/5448 (13%)	0.98 (0.88-1.08)	0.63
Death	1240/5493 (23%)	1263/5448 (23%)	0.97 (0.91-1.04)	0.45
Subsidiary outcomes				
Use of ventilation †	860/3564 (24%)	863/3441 (25%)	0.96 (0.89-1.04)	0.36
Non-invasive ventilation	822/3564 (23%)	821/3441 (24%)	0.97 (0.89-1.05)	0.43
Invasive mechanical ventilation	226/3564 (6%)	237/3441 (7%)	0.92 (0.77-1.10)	0.36
Successful cessation of invasive mechanical ventilation ‡	87/302 (29%)	112/315 (36%)	0.77 (0.59-1.03)	0.07
Renal replacement therapy §	258/5729 (5%)	249/5713 (4%)	1.03 (0.87-1.22)	0.71

Data are n (%) or n/N (%). RR=rate ratio for the outcomes of 28-day mortality, hospital discharge, and successful cessation of invasive mechanical ventilation, and risk ratio for other outcomes.

* Analyses exclude those on invasive mechanical ventilation at randomisation.

† Analyses exclude those on invasive or non-invasive ventilation at randomisation.

‡ Analyses exclude those not receiving invasive mechanical ventilation at randomisation.

§ Analyses exclude those on renal replacement therapy at randomisation.

631

632

633 **Figures**

634

635 **Figure 1: Trial profile - Flow of patients through the RECOVERY trial**

636 * Number recruited overall during period that patients could be recruited into

637 convalescent plasma comparison.

638 † A second randomisation to tocilizumab versus usual care in patients with hypoxia and

639 C-reactive protein ≥ 75 mg/L was introduced in protocol version 4.0. 426 patients in the

640 convalescent plasma arm were randomised to tocilizumab vs. 486 randomised to usual

641 care alone. 573 patients in the usual care arm were randomised to tocilizumab vs. 552

642 patients randomised to usual care alone.

643

644 **Figure 2: Effect of allocation to convalescent plasma on 28-day mortality**

645

646 **Figure 3: Effect of allocation to convalescent plasma on 28-day mortality by**
647 **prespecified characteristics at randomisation**

648 Subgroup-specific rate ratio estimates are represented by squares (with areas of the

649 squares proportional to the amount of statistical information) and the lines through them

650 correspond to the 95% CIs. The ethnicity, days since onset and use of corticosteroids

651 subgroups exclude those with missing data, but these patients are included in the

652 overall summary diamond. Information on use of corticosteroids was collected from 18

653 June 2020 onwards following announcement of the results of the dexamethasone

654 comparison from the RECOVERY trial.

655

656

657 **Figure 4: Convalescent plasma vs. usual care in patients hospitalised with COVID**

658 **– meta-analysis of mortality in RECOVERY and other trials**

659 * Log-rank O-E for RECOVERY, O-E from 2x2 tables for the other trials. RR is
660 calculated by taking $\ln RR$ to be $(O-E)/V$ with Normal variance $1/V$. Subtotals or totals
661 of $(O-E)$ and of V yield inverse-variance-weighted averages of the $\ln RR$ values.

662 † For balance, controls in the 2:1 study by Simonovich count twice in the control totals
663 and subtotal

664

Figure 1: Trial profile – Flow of participants through the RECOVERY trial

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.09.21252736>; this version posted March 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).





Figure 2: Effect of allocation to convalescent plasma on 28-day mortality



No. at risk

Convalescent plasma	5795	5154	4727	4486	4376
Usual Care	5763	5218	4744	4475	4341

Figure 3: Effect of allocation to convalescent plasma on 28-day mortality by prespecified characteristics at randomisation





Figure 4: Convalescent plasma vs usual care in patients hospitalised with COVID – Meta-analysis of mortality in RECOVERY and other trials



Heterogeneity between RECOVERY and previous trials: $\chi^2_1=0.8$

* Log-rank O-E for RECOVERY, O-E from 2x2 tables for the other trials. RR is calculated by taking $\ln RR$ to be $(O-E)/V$ with Normal variance $1/V$. Subtotals or totals of (O-E) and of V yield inverse-variance-weighted averages of the $\ln RR$ values.

† For balance, controls in the 2:1 study by Simonovich count twice in the control totals and subtotals.